Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma
Completed · Phase 1
Conditions studied: Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm
In brief
RATIONALE: Biological therapies, such as antithymocyte globulin may stimulate the immune system in different ways and stop cancer cells from growing. Sirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It may also prevent or reduce the side effects of antithymocyte globulin. Giving antithymocyte globulin together with sirolimus may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of antithymocyte globulin when given together with sirolimus in treating patients with relapsed multiple myeloma.
Key facts
- Study ID
- NCT00317798
- Run by
- University of Rochester
- People needed
- 18
- Starts
- 2006-04-01
- Expected to finish
- 2011-04-01
- Last updated by the study team
- 2011-08-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- James P. Wilmot Cancer Center at University of Rochester Medical Center — Rochester, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.